Printer Friendly

CYTOGEN ACQUIRES RIGHTS TO PAIN RELIEF AGENT FOR BONE CANCER

 PRINCETON, N.J., May 20 /PRNewswire/ -- CYTOGEN (NASDAQ: CYTO) announced today the acquisition of exclusive U.S. marketing rights to Samarium-153-EDTMP, a radiopharmaceutical developed by The Dow Chemical Company (NYSE: DOW) for the alleviation of bone pain associated with metastatic cancer.
 Samarium EDTMP is currently in advanced Phase III human clinical trials in the United States and Europe. An estimated 400,000 cancer patients per year contract bony metastases in the United States, including patients with breast, prostate and lung cancers, and more than half of them experience severe bone pain. Treatment for eliminating bone pain is often not effective and frequently progresses to the use of narcotics. These narcotic-based treatments, in most cases, are addictive and may cause incapacitation of the cancer patient.
 In a Phase I/II study of patients with metastatic bone pain, the product demonstrated either partial or complete pain relief in a majority of the evaluable patients, lasting for an average of four months. Responsibility for managing the Phase III clinical trials directed by Dow in both the United States and Europe transfers immediately to CYTOGEN. CYTOGEN expects to complete the double-blind, single-dose Phase III trials for the palliation of pain associated with bony metastases this year and to file a New Drug Application with the U.S. Food and Drug Administration in 1994. Additional human clinical trials to study the efficacy of Samarium EDTMP for tumor regression will begin soon.
 "This is an ideal product acquisition for us," stated CYTOGEN President Dr. Thomas J. McKearn. He continued, "Already in advanced Phase III human testing, Samarium EDTMP accelerates our cancer therapeutic program, and represents CYTOGEN's first product development efforts outside of monoclonal antibodies and MRU's. This addition expands our technological foundation, while maintaining our focus on cancer care."
 According to William Dowd, director of the Bioproducts Laboratory for Dow Central Research and Development in Midland, Mich., a key criteria in licensing this product was finding a company that could aggressively commercialize this technology. "CYTOGEN's experience with oncology products and in marketing short-lived radioisotopes provides an excellent fit. Dow has also been very impressed with CYTOGEN's aggressive clinical research and regulatory expertise," said Dowd.
 Terms of the agreement were not disclosed.
 CYTOGEN is a biopharmaceutical company engaged in the development of products for the targeted delivery of diagnostic and therapeutic substances directly to sites of disease. CYTOGEN uses its patented and proprietary "linker" technology primarily to develop specific cancer diagnostic imaging and cancer therapeutic products.
 The Dow Chemical Company is a $20 billion global operation with significant business activity in chemicals, plastics, pharmaceuticals, agricultural products and consumer specialties. Dow's expertise in biotechnology has been used for Research programs in industrial enzymes, biocatalysis, and agricultural and pharmaceutical applications.
 Non-media inquiries should also be directed to CYTOGEN at 609-987-8221.
 /delval/
 -0- 5/20/93
 /CONTACT: Mary Beals, director, Corporate Communications of CYTOGEN Corporation, 609-987-8221, or Beth Middleton, communications manager, R&D of The Dow Chemical Company, 517-636-2474/
 (CYTO)


CO: Cytogen Corporation; The Dow Chemical Company ST: New Jersey, Michigan IN: MTC SU: PDT

MP -- PH005 -- 3188 05/20/93 09:45 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 20, 1993
Words:514
Previous Article:PHILADELPHIA FED RELEASES MAY BUSINESS OUTLOOK SURVEY
Next Article:TADIRAN FIRST QUARTER INCOME FROM CONTINUING OPERATIONS ROSE 6.5 PERCENT
Topics:


Related Articles
CYTOGEN REPORTS ON BONE PAIN RELIEF AGENT
CYTOGEN UPDATES STOCKHOLDERS ON MARKETING OF ONCOSCINT(R) CR/OV, PRODUCT DEVELOPMENT ACTIVITIES & CYTORAD DEVELOPMENTS
CYTOGEN AND DUPONT MERCK FINALIZE AGREEMENT
CYTOGEN AND DUPONT MERCK FINALIZE AGREEMENT
CYTOGEN Receives FDA Clearance For Quadramet
New Treatment for Cancer Bone Pain Receives FDA Clearance; Quadramet May Offer New Hope for Pain Relief for Cancer Patients
European Study of CYTOGEN's Quadramet(R) Finds Significant Dose Response in The Relief of Bone Pain Caused by Metastatic Breast Cancer and Prostate...
Cytogen Reacquires Marketing Rights to QUADRAMET(R) Pain Therapy Product.
Cytogen Announces Agreement to Reacquire Marketing Rights to QUADRAMET(R) Pain Therapy Product.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters